look at gilead and arena. arena has an obesity drug that gilead has and also the hiv treatments.to you. >>> this is flirting for 20 for a couple days now. last time is settled above 20 was april 11th. the nasdaq, meanwhile, on pace for the lowest close in two months. nasdaq down seven points. a quarter of a percent lower. nasdaq will be down for a fourth session in a low. and the stock is not moving much. there has been a rough time the last few weeks but an estimated 500 protesters outside the shareholders meeting being held in charlotte, south carolina. a couple arrests have been made at this point. >> bank of america is a morally bankrupted institution that has been too large to fail. we don't think that as american taxpayers we should be propping up a financial institution and do you think it's different for b of a right now? >> i think the consistently worst offender and i was defrauded to the tune of thousands of dollars in illegal foreclosure fees and that's something that they settled for in civil cases and persistently done over and over again. we think there's a real pa

bristol-myers and gilead, merck, pfizer, gsk, abbot and rosche all cross products, their products in various ways in the hiv area or outside of the hiv area. and they're so often in bed with each other, back and forth, in some cases, one country will sell the drug in the united states and others will sell it in europe. or there might be a fixed dose combination that involves products from both in the united states, bristol-myers, and gillian. so it's hard to know, are they partners or are they competitors? and the prices would suggest they're more like partners than competitors. >> let me -- yes, dr. stiglitz. >> two comments i want to add. i think you were right in thinking about this as an experiment and thinking about how we can develop a better innovation system, not just for aids, but for health and beyond health for research more broadly. and i just wanted to reiterate that in thinking about the innovation system, there are a couple of other parts. the patent system will continue to play some role in, for instance, ideas that we haven't even thought about. in health, the price

that's what the fda will be looking at this week when it considers whether gilead sign yes, sirs shouldallowed -- sciences should be allowed to advertise their drug. at&t getting too into the home security business. digital -- let's users watch camera footage of their home and adjust temperature lighting remotely. change, dominoes announcing it plans to begin offering a pizza made with gluten-free crust. u part of a race to grab a bite of more than six billion dollar market. at the new york new york stock exchange i'm jane king. >>> good news for drivers. gas prices continue to fall. the u.s. average for regular dropped seven cents in the past two weeks diesel fell by three cents. san francisco no lodger the most expensive place in the country to fill up. chicago now has the heyest average price of $4.32. u.s. average $3.85. cheapest is sold in the nation's oil patch, tulsa, oklahoma, $3.40. >>> two cheetahs attacked a woman in south africa and her husband took pictures of the whole thing. emphasis on the whole thing. archie and violet got the chance to pet two supposedly tame cheetahs

it reminds me of gilead that took off because of its hiv drugs and never looked back.ow about genzyme? and alexion is doing $16 billion in sales. this is a riskier stock. i think it's still worth buying on the slightest pullback. even though vertex rallied 55% yesterday and 10% today, i think it's more attractive up here than it was on friday. the new drug makes this much better prospect but only on speculation. and only on a pullback. if you ever get that pullback. after the break i'll try to make you more money. >>> time for you to stop hating and learn to love short sellers for what they do best. they lend skepticism to the market. they warn, they give you a heads up. let's tick down the list. first fossil. there's no doubt this stock has been a rocket ship. however, the shorts have repeatedly warned they're an accessory business, which is all faddish and would eventually run ut of team. the stock got a 37% beheading. second there's mako surgical. the bears have been wise to this one for a while. as almost a third of the float has been sold short. mako announced a h

it reminds me of gilead, a biotech that took off because of its hiv franchise and never looked back.self to sanofi. and alexion is doing a billion in sales.ç this is a riskier stock. i think it's still worth buying on the slightest pullback. even though vertex rallied 55% yesterday and 10% today, i think it's more attractive up here than it was on friday. the new data makes this much better prospects but only for speculation and only on a pullback. if you ever get that pullback. after the break i'll try to make you more money. ale announcer) most life insurance companies look at you and just see a policy. at aviva, we do things differently. we're bringing humanity back to life insurance. that's why only aviva rewards you with savings for getting a check-up. it's our wellness for life program, with online access to mayo clinic. see the difference at avivausa.com. >>> time for you to stop hating and learn to love short sellers for what they do best. they lend skepticism to the market. they warn, they give you a heads up. today's actions is exhibit a. let's tick down the list. first fo

it reminds me of gilead, a biotech that took off because of its hiv franchise and never looked back. about genzyme? sold itself to sanofi. and alexion is doing a billion in sales. this is a riskier stock. i think it's still worth buying on the slightest pullback. even though vertex rallied 55% yesterday and 10% today, i think it's more attractive up here than it was on friday. the new data makes this much better prospects but only for speculation and only on a pullback. if you ever get that pullback. after the break i'll try to make you more money. [ female announcer ] letting her home be turned into a training facility? ♪ this olympian's mom has been doing it for years. she's got bounty. in this lab demo, one sheet of new bounty leaves this surface cleaner than two sheets of the leading ordinary brand. bounty has trap and lock technology to soak up big spills and lock them in. let the spills begin. p&g. proud sponsor of the olympic games. chocolate, chilies and something called kosmic mother funk all have in common? sam adams! last year we brewed more than one new beer every week. s

in fact foster city base gilead had previously said other clinical studies also support the use of this as part of a comprehensive prevention package in conjunction with condom and other intervention. >> we are just more responsible and is save lives and stm there's whole generation that is missing right now because we didn't have this the. >>reporter: fda approval as preventive drug could come as early as next month. in the newsroom, abc 7 news. >>> quick look at some news now from around the state. first of its kind ban on therapy aim at making gay people straight passed the final state senate committee today. measure now goes to the full senate. yahoo director who did not challenge inaccuracy in ceo thompson academic record will step down. director hart headed up the search committee that hired thompson who lied on his resum resume. >> 5 current former cal-trans employee have been arrested for theft and over time fraud at a big sur maintenance station. they are being held on bail of 1 million dollars each. >> 1300 damage tubes at the san onofre power plant in southern california will

combination by the leading one involves products from both in the united states bristol-myers and gileadrd to know are they partners, or are they competitors? and the prices would suggest they're more like partners than competitors. >> all right. let me -- yeah, dr. stiglitz. >> just two comments i want to add. you, i think, were right in thinking about this as an experiment, an innovation innovation. and thinking about how we can develop a better innovation system not just for aids, but for health and beyond health for research more broadly. and i just want to reiterate that in thinking about the innovation system, there are a couple of other parts. the patent system will continue to play some role in, for instance, ideas that we haven't even thought about. in health the price system is particularly well suited because we have a more well-formulated notion of what we need and, therefore, it's a particularly effective in that area. some other areas where, for instance, in climate change it can be particularly effective. we know what we need in terms of more efficient batteries. so there

also, shares of gilead sciences moving hire after an fda panel says their hiv drug should be approvedv patients. and scott thompson saying he never provided a resumÉ or incorrect statements to the company. also according to a wall street journal story by cara swisher, he was in interview where he was asked about this and talked at least about some of these issues. we had jeff sonnenfeld on earlier today and heap still says that is a serious question. >>> european equities this morning as can you see also in the red. the biggest drop may be coming there in athens, down 23.36%. argentina's government slapping restrictions on import of insurance hands. is it another insult. michelle caruso-cabrera is here with what this means on a grand scale. >> she brought us ham. >> it's going to be delicious. spaen is living an awful week, horrendous week. argentina launched a huge insult across the pan by banning the import of spanish ham. you have to understand that ham in spain is big. it's the combination of turkey on thanksgiving, hot dogs at a baseball game, multiplied by thousand dollars. it n

gilead actually one of the only stocks in the nasdaq this morning that was positive.ll day. fda advisory panel will take up two, one tomorrow and one on friday. >> bertha, thanks a lot. >>> want to get more to the markets with cyst verone. joins us here this morning at post nine. chris, always good to have you. >> thank you. >> let's tackle s&p first. >> sure. >> the first important number is still 1340. >> 1335 to 1340 is important. we need to put this in context. remember, this correction is not a week old, two weeks oel. we've made no price progress on the s&p 500 for 12 weeks. this has been two or three months in the building, not two or three weeks old. that's an important distinction to make. when you look at the other indices, no price context for the russell 2,000 for 15 weeks. >> let me stop you there. you mentioned -- looking at the s&p now. we've have not had to test that level for some time. russell, we have been back to 780 for some time now. >> tested 780 about four times over the next 12 weeks. i'm not convinced it's going to old a fifth. i think that m